| Clinical data | |
|---|---|
| Trade names | Monoferric, Monofer | 
| AHFS/Drugs.com | Monograph | 
| License data | |
| Routes of administration | Intravenous (IV) | 
| ATC code | 
 | 
| Legal status | |
| Legal status | |
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H34FeO16+3 | 
| Molar mass | 562.299 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Ferric derisomaltose (FDI), sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD).[3] It was approved for use in the United States in January 2020.[3][4][5] It is given intravenously.[3]
References
- ↑ "Monofer iron (as ferric derisomaltose) 1000 mg/10 mL solution for injection vial (290834)". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 9 April 2023.
- ↑ "Search Page - Drug and Health Product Register". 23 October 2014.
- 1 2 3 4 "Monoferric- ferric derisomaltose solution". DailyMed. 24 January 2020. Retrieved 16 February 2020.
- ↑  "Monoferric approval letter" (PDF). U.S. Food and Drug Administration (FDA). 16 January 2020. Retrieved 16 February 2020.  This article incorporates text from this source, which is in the public domain. This article incorporates text from this source, which is in the public domain.
- ↑ "Drug Approval Package: Monoferric Injection". U.S. Food and Drug Administration (FDA). 7 May 2020. Retrieved 13 August 2020.
External links
- "Ferric derisomaltose". Drug Information Portal. U.S. National Library of Medicine.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.